People
Our core team and board bring 50+ years of combined experience in insulin device innovation, regulatory excellence, global health access and lived patient experience — anchored in diabetes care. From Denmark to Mexico, India, Tunisia and Germany, we're united by one purpose: equal access to quality diabetes care globally.
Our team
-
Ole Kjerkegaard Nielsen
CEO & Co-Founder
Bringing 15+ years of diabetes care leadership from Novo and global health equity expertise to democratize insulin delivery worldwide.
-
Michael Ejstrup Hansen
CTO & Co-Founder
Mechanical engineering innovator and co-inventor of multiple Novo insulin device patents, bringing 25+ years of medical device development expertise to accessible diabetes technology.
-
Christian Christiansen
Senior Director of Operations
Medical device executive with 25+ years in engineering and operations. CEO of Nordic NeuroSTIM and MEDODAN. Expert in clinical testing, FDA/CE clearances, IP management, and international manufacturing. Proven track record scaling medical device startups globally.
-
Amin Zayani
Director, Product Management
Type 1 diabetes advocate and product development expert, combining lived experience with deep healthcare technology innovation from Novo and Lilly partnerships.
-
Aparajita Tatke
Director, Regulatory Affairs and Quality Assurance
Pharmaceutical sciences expert leading GO-Pen's global regulatory strategy, instrumental in securing FDA clearance and ensuring worldwide market access for accessible diabetes technology.
-
Janne Blomfeldt
Marketing Director
People-first commercial leader with 20+ years in medical devices, FMCG and product launches, helping start-ups and scale-ups define positioning, go-to-market strategy and launch plans.
-
Brit Larsen
Director of Communication
Strategic communication leader with 15+ years driving diabetes access initiatives at Novo and World Diabetes Foundation, involved in numerous innovative global health partnerships.
-
Miguel Galindo
Commercial Director
Healthcare communication expert with 16+ years helping medical speakers, physicians and organizations turn complex science into communication that connects and drives action.
-
Cathrine Marra
Regulatory Affairs and Quality Assurance
Quality assurance specialist supporting GO-Pens regulatory excellence through hands-on laboratory and pharmaceutical production experience, backed by an MSc in Biomaterial Engineering from DTU and published research in peer-reviewed journals.
-
Gustav Dahlgaard
Project Manager
Data analysis specialist supporting GO-Pen's strategic growth through analytical insights and business intelligence during the company's critical market expansion phase.
-
Elias Navntoft
Market Analyst
Market research specialist supporting GO-Pen's commercial strategy with market insights, competitor analysis and data-driven decision-making during the company's critical market expansion phase.
Contact -
Pia Thorbek
Senior Director, Medical Affairs
Former Novo Corporate Vice President with a PhD in medicinal chemistry and 35+ years in pharmaceuticals, spanning drug development, protein chemistry and medical devices. Senior advisor and mentor in life science startup development and regulatory strategy.
Our partners
We are teaming up with a range of talented and highly experienced people on our journey towards developing an affordable insulin pen for all
Board of Directors
-
Chair of the Board
Biotech executive with 15+ exits and 2 IPOs. CEO of Synact Pharma, took company public on Nasdaq Stockholm. Extensive experience scaling healthcare companies across Nordic markets and international expansion.
-
Board Director, Co-Founder
Mechanical engineer and co-inventor of multiple Novo Nordisk insulin device patents. 25+ years developing medical devices from concept through FDA clearance. Expert in accessible diabetes technology innovation.
-
CEO/CFO, Co-Founder
Healthcare innovation leader with extensive Novo Nordisk experience and field work in emerging markets. Specializes in sustainable healthcare solutions and developing market strategies for accessible diabetes care.
-
Board member
Biotech CEO and board member with extensive life sciences leadership experience. Former CEO of Immudex and current CEO of Furine ApS. Expert in regulatory affairs, drug development, and scaling biotech companies from early stage through commercialization, bringing strategic healthcare industry expertise.
-
Board member
Impact investor and entrepreneur specializing in tech-driven solutions for African markets. Co-founder of Carbory ApS and experienced board member across multiple startups. Brings strategic expertise in scaling businesses that address global health challenges while creating sustainable social and environmental impact.
-
Board member
CEO of AJ Vaccines serving 50+ countries through WHO/UNICEF partnerships. 25+ years pharmaceutical leadership including €500M+ international expansion. Expert in global healthcare market operations.
Advisory Board
-
CEO of Diabetes Center Berne and General Partner at Swiss Diabetes Venture Fund. Entrepreneurial leader with extensive pharma, biotech, and medical device expertise. Focuses on diabetes technology innovation and patient-centered business strategies, bringing deep industry knowledge and investment experience to diabetes care development.
-
Partner at Horten law firm specializing in intellectual property litigation and regulatory matters within Life Sciences. Expert in patent strategy, commercialization of IP rights, and complex regulatory compliance for startups to major companies, particularly in pharmaceuticals and medical devices.
-
Christina is a Swiss/European-based investor, board member, and executive advisor, known for her systemic approach to capital allocation. Working at the intersection of medicine, capital, and systems change, her approach is grounded in the conviction that long-term financial returns and measurable human outcomes are interdependent. Christina’s experience spans medicine, strategy, and leadership.